TickerWorth Open the interactive view →

Guardant Health, Inc. (GH) — Available-Data Snapshot

Updated Nov 10, 2026 · available-data snapshot · descriptive, not a DCF, not advice

Price
$158.79
Market cap
$21,482,057,728
52-week high
$191.05
52-week low
$74.55
Currency
USD
Exchange
NasdaqGS

We don't publish a discounted-cash-flow fair value for Guardant Health, Inc. (GH) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, GH trades at a recent price of $158.79, a market capitalisation of about $21,482,057,728, sitting 72% of the way up its 52-week range ($74.55–$191.05), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing GH's trading multiples against a sector benchmark. Here that gives P/S of 16.8× (richer than the peer median of 6.8×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

Finally, a price-based read — explicitly not a valuation. GH is in a mixed trend, trading -16.9% from its 52-week high. Over the past year the stock is +54.1%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

Relative valuation — GH vs peers

MultipleGHPeer median
P/S16.8×6.8×richer than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

We are not showing a price-to-book for this listing: the book value we have does not belong to the same share class as the price, so any ratio of the two would be arithmetic rather than a valuation.

Price-based snapshot

50-day avg
$169.32
200-day avg
$131.73
From 52-wk high
-16.9%
1-year momentum
+54.1%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive GH view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.